132 related articles for article (PubMed ID: 38599309)
1. GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression.
Khan B; Chen M; Wang H; Khan A; Hussain S; Shi J; Yang L; Hou Y
Eur J Pharmacol; 2024 Jun; 972():176565. PubMed ID: 38599309
[TBL] [Abstract][Full Text] [Related]
2. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Shi Y; Fu Y; Zhang X; Zhao G; Yao Y; Guo Y; Ma G; Bai S; Li H
Cancer Immunol Immunother; 2021 Jan; 70(1):61-73. PubMed ID: 32632663
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy.
Liang Y; Luo H; Li X; Liu S; Habib A; Liu B; Huang J; Wang J; Yi H; Hu B; Zheng L; Xie J; Zhu N
Front Immunol; 2024; 15():1367040. PubMed ID: 38745661
[TBL] [Abstract][Full Text] [Related]
4. The extracts of
Chang HL; Kuo YH; Wu LH; Chang CM; Cheng KJ; Tyan YC; Lee CH
Int J Med Sci; 2020; 17(7):939-945. PubMed ID: 32308547
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.
Voli F; Valli E; Lerra L; Kimpton K; Saletta F; Giorgi FM; Mercatelli D; Rouaen JRC; Shen S; Murray JE; Ahmed-Cox A; Cirillo G; Mayoh C; Beavis PA; Haber M; Trapani JA; Kavallaris M; Vittorio O
Cancer Res; 2020 Oct; 80(19):4129-4144. PubMed ID: 32816860
[TBL] [Abstract][Full Text] [Related]
6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
7. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Schaer DA; Geeganage S; Amaladas N; Lu ZH; Rasmussen ER; Sonyi A; Chin D; Capen A; Li Y; Meyer CM; Jones BD; Huang X; Luo S; Carpenito C; Roth KD; Nikolayev A; Tan B; Brahmachary M; Chodavarapu K; Dorsey FC; Manro JR; Doman TN; Donoho GP; Surguladze D; Hall GE; Kalos M; Novosiadly RD
Clin Cancer Res; 2019 Dec; 25(23):7175-7188. PubMed ID: 31409612
[TBL] [Abstract][Full Text] [Related]
8. PPARγ agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation.
Jia X; Qian J; Chen H; Liu Q; Hussain S; Jin J; Shi J; Hou Y
Eur J Pharmacol; 2023 Jul; 950():175749. PubMed ID: 37105516
[TBL] [Abstract][Full Text] [Related]
9. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
Zhang H; Xia Y; Wang F; Luo M; Yang K; Liang S; An S; Wu S; Yang C; Chen D; Xu M; Cai M; To KKW; Fu L
Adv Sci (Weinh); 2021 May; 8(10):2003404. PubMed ID: 34026438
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Wu Y; Chen W; Xu ZP; Gu W
Front Immunol; 2019; 10():2022. PubMed ID: 31507611
[TBL] [Abstract][Full Text] [Related]
13. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.
Beyrend G; van der Gracht E; Yilmaz A; van Duikeren S; Camps M; Höllt T; Vilanova A; van Unen V; Koning F; de Miranda NFCC; Arens R; Ossendorp F
J Immunother Cancer; 2019 Aug; 7(1):217. PubMed ID: 31412943
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
17. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
Altves S; Guclu E; Yetisgin E; Bilecen K; Vural H
World J Microbiol Biotechnol; 2024 May; 40(7):204. PubMed ID: 38755413
[TBL] [Abstract][Full Text] [Related]
19. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
